Working Groups in the CBT

CBT includes seven research sections to work with PIs, post doctoral fellows, and students to address complex research goals. CBT provides the expertise and state-of-the-art resources needed to develop recombinant protein expression vectors as well as express (bioreactors/fermenters), purify (HPLC/FPLC), crystallize, and characterize (X-ray and NMR) proteins, protein complexes, nucleic acid complexes, as well as complexes involving small molecule inhibitors (i.e. drugs) and biological therapeutics. The center also has dedicated space for high-throughput screening and target validation at the biochemical and cellular levels (robots, plate readers, tissue culture suites). The center can also produce constructs/targeted ES cells for generating new mouse models for in vivo testing.

The detailed resources for the specific sections are outlined on their individual pages:

  • Computer-Aided Drug Design (Section Leader: Alex MacKerell Jr., PhD): providing computational approaches to speed drug discovery and design.
  • Genomics & Bioinformatics (Section Leader: Claire M. Fraser, Ph.D.): CBT works directly with The Institute for Genome Sciences (IGS) to generate high quality genomic data genome annotation and analysis, IT infrastructure, web, and database services.
  • In Vivo Biology & Drug Testing (Section Leader: Danna Zimmer, Ph.D.): screening and pre-clinical evaluation of chemical probes and lead compounds from drug discovery efforts as well as diagnostics.
  • Medicinal Chemistry (Section Leader: Vincent Njar, Ph.D.): discovering and developing new drugs for improving human health.
  • Protein Production & Biophysics (Section Leader: David Weber, Ph.D.): producing purified proteins for investigators, including for advanced uses in other CBT sections (i.e. Structural Biology (SB) for NMR and crystallization and Target Validation & Screening (TVS) for use in in vitro assays),
  • Structural Biology (Section Leader: Kristen Varney, Ph.D.): determining three-dimensional structures of protein and other macromolecules to understand the structural basis for biological function and dynamics.
  • Target Validation & Screening (Section Leader: Paul Wilder, Ph.D.): identifying therapeutic targets and screens for chemical perturbagens as a step towards developing new drugs and therapies.